*GLAND PHARMA - CONCLUSION OF US FDA INSPECTION AT COMPANY’S JNPC FACILITY, VISAKHAPATNAM
*GLAND PHARMA - INSPECTION WAS CONCLUDED WITH THREE FORM 483 OBSERVATIONS
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 25-FEB-202510:34:53 GMT